Patents by Inventor Isao Sakurada
Isao Sakurada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230190943Abstract: Provided is water-soluble compound that can be used in a sustained-release preparation and is capable of stably releasing a fixed amount of an active ingredient in vivo by using the novel potential base material option of alginic acid as the base material.Type: ApplicationFiled: February 2, 2023Publication date: June 22, 2023Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Shoji FURUSAKO, Isao SAKURADA
-
Publication number: 20210000968Abstract: Provided is water-soluble compound that can be used in a sustained-release preparation and is capable of stably releasing a fixed amount of an active ingredient in vivo by using the novel potential base material option of alginic acid as the base material.Type: ApplicationFiled: September 17, 2020Publication date: January 7, 2021Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Shoji FURUSAKO, Isao SAKURADA
-
Patent number: 10189819Abstract: The present invention provides a compound of Formula I, and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.Type: GrantFiled: December 7, 2015Date of Patent: January 29, 2019Assignees: Merck Sharp & Dohme, Corp., Mochida Paraceuticals Co., Ltd.Inventors: Ting Zhang, Yi-Heng Chen, Liangqin Guo, Alan Hruza, Tianying Jian, Bing Li, Dongfang Meng, Dann L. Parker, Edward C. Sherer, Harold B. Wood, Isao Sakurada
-
Patent number: 9969724Abstract: In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.Type: GrantFiled: April 10, 2015Date of Patent: May 15, 2018Assignees: Merck Sharp & Dohme Corp., Mochida Pharmaceutical Co., Ltd.Inventors: Isao Sakurada, Tomokazu Hirabayashi, Yoshitaka Maeda, Hiroshi Nagasue, Takashi Mizuno, Jiayi Xu, Ting Zhang, Cameron Smith, Dann Parker
-
Publication number: 20180030036Abstract: The present invention provides a compound of Formula I, and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.Type: ApplicationFiled: December 7, 2015Publication date: February 1, 2018Applicants: MERCK SHARP & DOHME CORP., MOCHIDA PHARMACEUTICAL CO., LTDInventors: Ting Zhang, Yi-Heng Chen, Liangqin Guo, Alan Hruza, Tianying Jian, Bing Li, Dongfang Meng, Dann L. Parker, Edward C. Sherer, Harold B. Wood, Isao Sakurada
-
Patent number: 9808445Abstract: In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.Type: GrantFiled: April 10, 2015Date of Patent: November 7, 2017Assignees: Merck Sharp & Dohme Corp., Mochida Pharmaceutical Co., Ltd.Inventors: Isao Sakurada, Tomokazu Hirabayashi, Yoshitaka Maeda, Hiroshi Nagasue, Takashi Mizuno, Jiayi Xu, Ting Zhang, Cameron Smith, Dann Parker
-
Publication number: 20170129880Abstract: In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.Type: ApplicationFiled: April 10, 2015Publication date: May 11, 2017Inventors: Isao Sakurada, Tomokazu Hirabayashi, Yoshitaka Maeda, Hiroshi Nagasue, Takashi Mizuno, Jiayi Xu, Ting Zhang, Cameron Smith, Dann Parker
-
Publication number: 20170027916Abstract: In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.Type: ApplicationFiled: April 10, 2015Publication date: February 2, 2017Applicants: Merck Sharp & Dohme Corp., Mochida Pharmaceutical Co., Ltd.Inventors: Isao Sakurada, Tomokazu Hirabayashi, Yoshitaka Maeda, Hiroshi Nagasue, Takashi Mizuno, Jiayi Xu, Ting Zhang, Cameron Smith, Dann Parker
-
Patent number: 8816090Abstract: This invention relates to compounds of the formula (I): wherein A, B, R1, R4, m, and n are each as described herein or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 receptor activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central 10 nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.Type: GrantFiled: February 15, 2006Date of Patent: August 26, 2014Assignee: Pfizer Inc.Inventors: Hirohide Noguchi, Isao Sakurada, Chikara Uchida, Nobuaki Waizumi
-
Publication number: 20130184294Abstract: The present invention relates to compounds of Formula I as described herein or a pharmaceutically acceptable salt thereof, pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof and methods of treating a disease, disorder, or condition of the central nervous system, including bipolar disorder, depressive disorders, anxiety disorders, cognitive disorders, pain disorders, urogenital disorders, and epilepsy, among the other diseases, disorders or conditions discussed herein as mono-therapy or in combination with another active pharmaceutical ingredient.Type: ApplicationFiled: September 7, 2011Publication date: July 18, 2013Applicant: Pfizer Inc.Inventors: Isao Sakurada, Lei Zhang
-
Publication number: 20080207690Abstract: This invention relates to compounds of the formula (I): wherein A, B, R1, R4, m, and n are each as described herein or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 receptor activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central 10 nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.Type: ApplicationFiled: February 15, 2006Publication date: August 28, 2008Inventors: Hirohide Noguchi, Isao Sakurada, Chikara Uchida, Nobuaki Waizumi
-
Publication number: 20070167452Abstract: The present invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt or solvate thereof, to processes for the preparation of, intermediates used in the preparation of, compositions containing such compounds and the uses of such compounds as antagonists of the NMDA NR2B receptor.Type: ApplicationFiled: February 1, 2005Publication date: July 19, 2007Inventors: Makoto Kawai, Mitsuhiro Kawamura, Asato Morita, Isao Sakurada
-
Publication number: 20040204409Abstract: This invention provides a compound of the formula (I): 1Type: ApplicationFiled: April 2, 2004Publication date: October 14, 2004Inventors: Kazuo Ando, Makoto Kawai, Mitsuhiro Kawamura, Miyako Matsumizu, Asato Morita, Isao Sakurada